XRCC2 and central nervous system cancer: Consistently, the expression level of XRCC2 in recurrent gliomas was higher than that in primary gliomas, and this was maintained for several histological subtypes Fig. 4E, G. Interestingly, the presence of IDH mutation and 1p/19q co-deletion negatively correlated with XRCC2 expression.